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Neonatal engraftment by oligodendrocyte progenitor
cells (OPCs) permits the myelination of the congeni-
tally dysmyelinated brain. To establish a potential
autologous source of these cells, we developed
a strategy by which to differentiate human induced
pluripotent stem cells (hiPSCs) into OPCs. From
three hiPSC lines, as well as from human embryonic
stem cells (hESCs), we generated highly enriched
OLIG2+/PDGFRa+/NKX2.2+/SOX10+ human OPCs,
which could be further purified using fluorescence-
activated cell sorting. hiPSC OPCs efficiently differ-
entiated into both myelinogenic oligodendrocytes
and astrocytes, in vitro and in vivo. Neonatally en-
grafted hiPSC OPCs robustly myelinated the brains
of myelin-deficient shiverer mice and substantially
increased their survival. The speed and efficiency
of myelination by hiPSC OPCs was higher than
that previously observed using fetal-tissue-derived
OPCs, and no tumors from these grafts were noted
as long as 9 months after transplant. These results
suggest the potential utility of hiPSC-derived OPCs
in treating disorders of myelin loss.
INTRODUCTION
A number of strategies have been developed for the cell-based
repair of demyelinated lesions of both the brain and spinal cord
(Ben-Hur and Goldman, 2008; Franklin and Ffrench-Constant,
2008; Goldman et al., 2012). In particular, human glial progenitor
cells capable of oligodendrocytic maturation and myelination
have been derived from both fetal and adult human brain tissue
(Dietrich et al., 2002; Roy et al., 1999; Windrem et al., 2004), as
well as from human embryonic stem cells (hESCs) (Hu et al.,
2009b; Izrael et al., 2007; Keirstead et al., 2005), and have
proven effective in experimentalmodels of both congenitally dys-
myelinated (Simet al., 2011;Windremet al., 2004;Windremet al.,
2008) and adult demyelinated (Windrem et al., 2002) brain and
spinal cord. Yet these successes in immunodeficient mice252 Cell Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Incnotwithstanding, immune rejection has thus far hindered the
use of allogeneic human cells as transplant vectors. Concern
for donor cell rejection has been especially problematic in re-
gards to adult demyelinating diseases such asmultiple sclerosis,
in which the inflammatory processes underlying the disorders
can present an intrinsically hostile environment to any allogeneic
graft (Keyoung and Goldman, 2007).
To address this issue, we sought to develop a robust protocol
for the scalable production of myelinogenic oligodendrocytes
(OLs) from skin-derived human induced pluripotent stem cells
(hiPSCs). By constructing hiPSCs from skin or blood derived
from a particular patient, onemay hope to generate sufficient oli-
godendrocyte progenitor cells (OPCs) to provide that patient
with myelinogenic autografts largely, though perhaps not com-
pletely, free of rejection risk. To this end, in this study we devel-
oped protocols by which we have generated highly enriched
populations of human OPCs from multiple lines of both hiPSCs
and hESCs. These cells reliably progress through the serial
stages of neural stem cell, glial progenitor cell, and both oligo-
dendrocytic and astrocytic differentiation in vitro. On that basis,
we assessed the myelination competence of the hiPSC-derived
OPCs (hiPSC OPCs) in a genetic model of congenital hypomye-
lination, the shiverer mouse, and established their ability to effi-
ciently and robustly myelinate the hypomyelinated shiverer brain
with no evidence of either tumorigenesis or heterotopic nonglial
differentiation. The transplanted animals survived significantly
longer than their untreated counterparts, and many were spared
early death, a striking clinical rescue from a fatal hereditary
disorder via an iPSC-based strategy. These data thus strongly
support the utility of hiPSCs as a feasible and effective source
of both OPCs and their derived myelinogenic central OLs and
suggest the potential of these cells as therapeutic vectors in
disorders of central myelin.
RESULTS
Human iPSCs Can Be Efficiently Directed to Glial
Progenitor Cell Fate
We used four different iPSC lines from three different sources
for this study; these included WA09/H9 hESCs (Thomson
et al., 1998); keratinocyte-derived K04 hiPSCs (Maherali et al.,
2008); and fibroblast-derived C14 and C27 hiPSCs (Chambers
et al., 2009). We selected specific features of several published.
Figure 1. hiPSCs Can Be Directed into OPC Fate
(A) A schematic protocol for directed differentiation of hiPSCs into OPCs. Embryoid bodies (EBs) were differentiated from undifferentiated hiPSCs (stage 1) from
DIV 0–5. EBs were then differentiated as neuroepithelial (NE) cells in neural induction media (NIM; see Experimental Procedures) with bFGF.
(B–D) Undifferentiated hiPSCs (stage 1) and hiPSC colonies expressed the pluripotency markers SSEA4 and OCT4. (B) Phase contrast. (C) SSEA4 (red); DAPI
(blue). (D) OCT4 (green); DAPI (blue).
(E–G) EBs (E) and neuroepithelial cells (F and G) could be generated from hiPSCs (stages 2 and 3). hiPSC-derived neuroepithelial cells at this stage expressed the
neuroepithelial markers PAX6 and SOX1. (E) Phase contrast. (F) PAX6 (green). (G) SOX1 (red).
(H and I) OLIG2+ andNKX2.2 early glial progenitor cells appeared under the influence of retinoic acid (RA) and purmorphamine, a small-molecule agonist of sonic
hedgehog signaling. By stage 4, OLIG2 was expressed in early pre-OPCs, which then serially developed NKX2.2 expression. (H) OLIG2 (red). (I) NKX2.2 (green).
(J) OLIO2+/NKX2.2 early pre-OPCs were differentiated into later-stage OLIG2+/NKX2.2+ pre-OPCs when RA was replaced by bFGF at stage 5. OLIG2 (red);
NKX2.2 (green).
(K–M) Pre-OPCs were further differentiated into bipotential OPCs in GIM (glial induction media; see Experimental Procedures) supplemented with PDGF-AA, T3,
NT3, and IGF. Stage 6 was extended as long as 3–4 months for maximization of the production of myelinogenic OPCs. By the time of transplant, these cells
expressed not only OLIG2 and NKX2.2 (K), but also SOX10 (L) and PDGFRa (M). By the end of stage 6, hiPSC OPCs could be identified as OLIG2+/NKX2.2+/
SOX10+/PDGFRa+. (K) OLIG2 (red); NKX2.2 (green). (L) SOX10 (red); NKX2.2 (green). (M) PDGFRa (red), OLIG2 (green).
(N–P) In vitro terminal differentiation of hiPSCOPCs into hiPSC-derived OLs (hiOLs), identified by O4+ (N) andMBP+ (O). OLs and GFAP+ astrocytes (P) arose with
reduction in glial mitogens. (N) O4 (green). (O) MBP (red). (P) GFAP(green); DAPI (blue).
Scale: 100 mm (B–N, P) and 25 mm (O). See also Figure S1.
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(Hu et al., 2009b; Izrael et al., 2007) and then optimized the
resultant hybrid protocol for use with WA09/H9 hESCs. We
then modified the resultant protocol to further optimize its effi-
ciency with the three hiPSC lines, which were derived in different
labs, from different cell sources, and using different reprogram-
ming protocols (Chambers et al., 2009; Maherali et al., 2008)
(Figure S1 available online). We found that the resultant six-stage
OPC differentiation protocol, which spans a range of 110–
150 days in vitro as detailed in the Supplemental Experimental
Procedures and schematized in Figure 1, efficiently generatedCehuman OPCs (hOPCs) as well as their mature progeny, including
both astrocytes and OLs, from hESCs and hiPSCs alike (Figures
1B–1P). Its efficiency of OPC production, as defined by the inci-
dence of OLIG2+/NKX2.2+ gliogenic (Qi et al., 2001; Zhou et al.,
2001; Zhou et al., 2000) cell clusters in stage 6, ranged from
45.4 ± 20.3% in WA09/H9-derived hESCs to 73.8 ± 8.7%,
78.9 ± 6.1%, and 79.5 ± 8.5% in K04-, C14-, and C27-derived
OPCs, respectively (all data are provided as means ± SEM;
Figures 2A and S2). Thus, each of the hiPSC and hESC lines
could be directed into highly enriched preparations of OLIG2+/
PDGFRa+/NKX2.2+/SOX10+ OPCs. Indeed, the efficiencies ofll Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inc. 253
Figure 2. Both Astrocytes and OLs Are Effi-
ciently Generated from hiPSC OPCs
(A) Expression of neural markers during induction
of oligodendroglial-lineage hiPSC-derived neuro-
epithelial cells in stage 3, pre-OPCs in stages 4
and 5, and OPCs in stage 6. Cultures were
immunostained for PAX6 and SOX1, or OLIG2 and
NKX2.2, respectively. The proportion of immuno-
positive clusters for each marker set were scored
for each hiPSC line. At least three repeats in each
group were performed; data are provided as
means ± SEM. In stage 6, gliogenic clusters were
dissociated to single-cell suspensions and plated
in GIM, resulting in the terminal differentiation of
both astrocytes and myelinogenic OLs.
(B and C) GFAP+ astrocytes were evident in cul-
tures of hiPSC OPCs by 95 DIV; C27-derived (B)
and K04-derived (C) astrocytes are shown here.
(D) Proportion of GFAP+ astrocytes among all
cultured cells at 95 DIV; the remainder expressed
oligodendroglial lineage markers (means ± SEM;
see Figure S2I). ICC, immunocytochemistry.
(E–J) Later in stage 6 (160 DIV), hiPSC-derived
OPCs differentiated as both O4+ (F and G) and
MBP+ (G) OLs. (H–J) When cocultured with human
fetal cortical neurons, hiPSC OPCs derived from
C27 (H), C14 (I), and K04 (J) hiPSCs all generated
MBP+ myelinogenic OLs that engaged NF+ axons
(MBP, red; NF, green).
Scale: 50 mm. See also Figure S2.
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nocytes (K04 cells) or fibroblasts (C14 and C27 cells), were con-
sistently higher than that of WA09/H9 hESCs.
Both Astrocytes and OLs Are Efficiently Derived from
hiPSC-Derived hOPCs
Both in vitro and in vivo, hiPSC OPCs readily differentiated into
astrocytes as well as OLs. GFAP-defined astroglia first appeared
by 70 days in vitro (DIV), significantly earlier than OLs did. By late
stage 6, at 120 DIV, GFAP+ astrocytes were found to be abun-
dant when gliogenic spheres were plated onto a polyornithine/
laminin-coated surface (Figures 2B–2D). By that time, GFAP+
cells comprised 40%–50% of cells in OPC-induced cultures,
across all cell lines (Figure 2D). Quantitative RT-PCR (qRT-254 Cell Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inc.PCR) confirmed the upregulation of
GFAP messenger RNA (mRNA) expres-
sion during OPC differentiation in all cell
lines (Table S1A).
The production of OLs from hESC-
and hiPSC-derived OPCs was triggered
by the withdrawal of gliogenic growth
factors to half-normal levels (see Experi-
mental Procedures). When hiPSC OPCs
were exposed to those conditions for
2 weeks, a proportion matured into O4+
and/or myelin basic protein (MBP)+ OLs
(Figures 2E–2G). According to flow cy-
tometry, O4+ OLs in C27, C14, and K04
hiPSC-derived OPC cultures respectively
comprised 11.9 ± 3.8%, 4.1 ± 0.9%, and7.6 ± 1.5% of all cells (at 194 ± 15, 186 ± 14, and 205 ± 14 DIV,
respectively; means ± SEM) (Figure 3A; Table S1B). Of note, our
culture conditions favored initial oligodendrocytic differentiation,
but not postmitotic oligodendrocytic survival, because our focus
was on preparing populations of transplantable lineage-biased
progenitors and immature oligodendroglia rather than more
mature—but less transplantable—process-bearing OLs.
OPCs Could Be Isolated from hiPSC Cultures by
CD140a- and CD9-Directed Fluorescence-Activated
Cell Sorting
Flow cytometry for A2B5, CD140a/PDGFaR, and the tetraspanin
CD9 (Berry et al., 2002; Terada et al., 2002) was next used
for identifying and quantifying hiPSC OPCs in stage 6 culture
Figure 3. OPCs Can Be Isolated from Mixed hiPSC Culture by CD140a- and CD9-Directed FACS
(A) hiPSC OPC-derived OLs were recognized and isolated by FACS using monoclonal antibody O4, which recognizes oligodendrocytic sulfatide. The incidence
of O4+ oligodendroglia varied across different hiPSC lines, from 4% to 12% (see Table S1; n = 4–7 experiments).
(B) OPCs derived from hiPSCs (C27 and K04) were readily recognized with the cell-surface marker A2B5.
(C) OPCs derived from either hiPSCs (C27 and K04) or hESCs (WA09/H9) were readily recognized with cell-surface markers, PDGFRa (CD140a), and CD9 by
FACS analysis. The relative proportions of CD140a, CD9, and CD140a/CD9 double-labeled cells varied across the different cell-line-derived OPCs (n = 4–7
experiments).
See also Tables S1A and S1B.
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and K04 hiPSCs respectively comprised 33.0 ± 10.3%, 32.8 ±
12.0%, and 41.1 ± 6.1% of all cells, compared to 37.5 ±
10.2% of H9-derived cells (Figure 3C; Table S1C). The CD9+
fraction of CD140a+ cells, which defined a later-stage pool of
OPCs, comprised 24.0 ± 8.0% and 12.4 ± 2.3% of cells in stage
6 C27 and K04 hiPSC cultures, respectively; matched cultures of
H9-derived OPCs included 15.0 ± 4.9% CD9+/CD140a+ cells
(Figure 3C; Table S1C; n = 4–7 repeats each). Thus, hiPSC
OPCs could be identified and isolated at different stages ofCelineage restriction, which were serially represented by A2B5,
CD140a, CD9, and O4. Selection based on these epitopes
permits the isolation of relatively pure populations of hiPSC
OPCs while removing residual undifferentiated cells from the
isolate.
hiPSC-Derived OLs Generated MBP in Contact with
Human Axons In Vitro
We next sought to examine the ability of hiPSC OLs to myelinate
axons in vitro. hiPSC OPCs from each cell line were coculturedll Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inc. 255
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tional age (g.a.) fetal brain using polysialyted neural cell adhesion
molecule (PSA-NCAM)-directed selection (Windrem et al., 2008).
The neurons were cultured on laminin for 10–14 days to allow
phenotypic maturation and fiber extension and were confirmed
to be free of tissue-derived OLs by O4 immunolabeling. hiPSC
OPCs were then prepared as clusters of 50–100 mm in diameter
and cocultured with the fetal neurons for 4 weeks; the cultures
were then immunolabeled for MBP and neurofilament (NF).
Confocal imaging revealed abundant MBP+ processes that
contacted axons and initiated ensheathment (Figures 2H–2J),
though unambiguous myelin formation was not noted at the
time points imaged. Thus, to better assess myelinogenesis by
hiPSC OPCs, we next evaluated their engraftment and myelina-
tion in vivo.
hiPSC OPCs Efficiently and Functionally Myelinated the
Shiverer Brain
To definitively establish the myelination competence of hiPSC
OPCs, we transplanted them into newborn homozygous shiverer
(shi/shi) 3 rag2/ immunodeficient mice. For this experiment,
the mice were implanted with 100,000 hiPSC-derived OPCs
bilaterally into the corpus callosum (n = 4–7 mice per hiPSC
line for K04, C27, and C14 hiPSC-derived OPCs), using previ-
ously described methods (Windrem et al., 2008). At 3 or
4.5 months of age, the mice were killed and their brains were
analyzed in terms of donor cell distribution and density, myelin
production and the proportion of myelinated axons, and nodal
reconstitution. All three of the hiPSC line-derived OPCs were
able to robustly myelinate the recipient brains; from each line,
high donor cell densities and widespread dispersal were ob-
served throughout the forebrain white matter (Figures 4A and
4B). C27, C14, and K04 hiPSC OPC-derived oligodendrocytic
differentiation and myelination were analogous in extent, with
robust myelination of the corpus callosum and capsules (Figures
4C, 4E, 4H, 5B, 5G, and 5J). As a result of the superior initial neur-
alization of these two lines relative to C14, we achieved higher
net yields of OPCs with C27 and K04 hiPSCs and hence only
pursued quantitative assessment of myelination in recipients of
C27 or K04 hiPSC OPCs.
Quantitative histology revealed that within the corpus callosa
of 3 month (13 week)-old shiverer recipients, C27 and K04
hiPSC-derived OPCs and oligodendroglia, defined as human
nuclear antigen (hNA)+/OLIG2+, achieved densities of 29,498 ±
13,144 and 37,032 ± 8,392 cells/mm3, respectively. Among
these, 7,298 ± 2,659 (C27) and 2,328 ± 650 (K04) cells/mm3 ex-
pressed MBP; these comprised 10.9 ± 5.1% (C27) and 4.7 ±
1.1% (K04) of all donor cells within the sampled midline of
the corpus callosum at the 13 week time point. To assess the
myelination efficiency in terms of the proportion of axons
myelinated, we next used confocal analysis to quantify the
fraction of callosal axons ensheathed by hiPSC oligodendroglia
in the three mice engrafted with C27 hiPSC-derived OPCs. At
the 13 week time point analyzed, 17.2 ± 7.2% of host mouse
axons were ensheathed within the three sampled callosa
(Figure 5B). Remarkably, the density of hiPSC-OPC donor-
derived myelination and the proportion of ensheathed axons
at 13 weeks proved as high as, and perhaps exceeded, those
achieved by OPCs derived from second-trimester fetal brain256 Cell Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inctissue, whether isolated as A2B5+/PSA-NCAM or CD140a+
cells (Sim et al., 2011; Windrem et al., 2004; Windrem et al.,
2008).
hiPSC OPCs Efficiently Generated Astrocytes and OLs
In Vivo
Besides the large numbers of hiPSC OPCs that differentiated as
myelinogenic OLs in the shiverer mouse brain, large numbers
also remained as resident OLIG2+ and NG2+ progenitor cells,
and many OPCs of all three hiPSC lines differentiated as astro-
cytes as well, particularly as fibrous astrocytes of the white
matter (Figures 4D, 4F, and 4I). When hiPSC-OPC-transplanted
micewere assessed at 13weeks after neonatal graft, most donor
cells persisted as progenitors or had initiated oligodendroglial
differentiation; by that time point, the net proportion of OLIG2+
cells, which included both OPCs and oligodendroglia, arising
from all K04 and C27 transplanted cells was 78.7 ± 2.4%,
whereas the remainder were largely donor-derived GFAP+ astro-
glia (Table S2).
Interestingly, despite the widespread infiltration of the recip-
ient brains by hiPSC OPCs, substantial astrocytic differentiation
was noted by those cells within the presumptive white matter,
within which the donor cells differentiated as morphologically
apparent fibrous astrocytes, in close association with hiPSC-
derived OLs. These hiPSC-derived astrocytes might have been
generated from lineage-restricted hiPSC-derived astrogliogenic
precursors or by astrocytic differentiation in situ from still-
bipotential hOPCs. In either case, by 3 months after neonatal
transplant, the callosal and capsular white matter of shiverer
recipients of OPC grafts derived from all three hiPSC lines man-
ifested human astrocytic scaffolds harboring densely engrafted
myelinogenic OLs, in each case yielding substantially recon-
structed and densely myelinated central white matter (Figures
4D, 4F, and 4I).
Neonatal Engraftment with hiPSC OPCs Could Rescue
the Shiverer Mouse
We next asked whether the robust engraftment and myelina-
tion noted in transplanted shiverer mice were sufficient to
ameliorate neurological deterioration and prolong the survival
of shiverer mice, which typically die by 20 weeks of age. To
this end, we transplanted a set of 22 neonatal homozygous
shiverer 3 rag2 nulls with 300,000 C27-derived hiPSC OPCs
using a five-site forebrain and brainstem injection protocol that
achieves whole-neuraxis engraftment via transplanted OPCs
(Figures 6A–6D) (Windrem et al., 2008). A matched set of 19
littermate controls were injected only with saline, and both
sets were housed without further manipulation. Predictably,
the 19 unimplanted shiverer controls died before 5 months of
age, with a median survival of 141 days. In contrast, 19 of the
22 implanted mice lived longer than the longest-lived control
mouse. The transplanted mice exhibited greatly prolonged
survival (Figure 6E), with reduced death over our 9 month period
of observation, after which the experiment was terminated so
that surviving mice could be processed for both immuno-
histochemical assessment of late-stage myelination and nodal
reconstitution and for ultrastructural analysis (see next section).
Comparison of the Kaplan-Meier survival plots of transplanted
and control mice revealed a highly significant difference (chi.
Figure 4. hiPSCs Migrate Widely and Differentiate as Astroglia and Myelinogenic OLs
hiPSCOPCs generated from all three hiPSC linesmigrated throughout the shiverer brain, engraftingmost densely in whitematter. Distributions of C27 (A) and K04
(B) hiPSC-derived OPCs are shown (hNA+, red, mapped in Stereo Investigator). By 13 weeks of age, C27 hiPSC OPCs (C), K04 hiPSC OPCs (E and G), and C14
hiPSC OPCs (H) matured into MBP-expressing oligodendroglia (green) throughout the subcortical white matter, including callosal and capsular (C, E, and H) as
well as striatal (G) tracts. In these 13-week-old shiverer mouse recipients, C27 (D), K04 (F), and C14 (I) hiPSC-derived OPCs also differentiated as astroglia
(human-specific GFAP, green), especially as fibrous astrocytes in the central white matter.
Scale: 100 mm (C–I). See also Table S2.
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0.0001) (Figure 6E). Those transplanted mice that survived
beyond 6 months uniformly exhibited substantial myelination
of the brain, brainstem, and cerebellum (Figures 6A–6D and
S3). Remarkably, the time-point-matched degree of cerebralCemyelination, as well as the proportion of shiverers alive at any
given time point, was greater in hiPSC-OPC-engrafted mice
than in mice previously engrafted with fetal-human-tissue-
derived, A2B5-sorted OPCs (Windrem et al., 2008), which had
otherwise been treated identically.ll Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inc. 257
Figure 5. hiPSC OPCs Robustly Myelinate In Vivo
Confocal images of the callosal and capsular whitematter ofmice engraftedwith hiPSCOPCs derived from all three tested hiPSC lines demonstrate dense donor-
derivedmyelination: (A and B) C27-derived, (E–G) K04-derived, and (I and J) C14-derived. (A), (G), and (J) show abundant, donor-derivedMBP expression (green)
by C27, K04, and C14 hiPSC OPCs (hNA, red), respectively. Representative z stacks of individual hNA+ OLs are shown as asterisks in (A) and (E). By the 19 week
time point assessed here, C27 (B), K04 (F and G), and C14 (J) hiPSC oligodendroglia robustly myelinated axons (NF, red). hiPSC-derived oligodendroglial
morphologies are exemplified in panels (F) (K04) and (I) (C14); (F) shows multiaxon myelination by single OLs in the striatum.
hiPSC OPCs also generated astroglia (C, C27; H, K04), which exhibited the complex fibrous morphologies typical of human astrocytes (human-specific GFAP,
green). Many cells also remained as progenitors, immunostaining for NG2 (D, C27) and human-specific PDGFRa (K, C14).
Scale: 50 mm (A–C, G, J); 20 mm (C–F, H, K); and 10 mm (I, insets to A and E).
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with Nodal Reconstitution
In light of the markedly extended survival of hiPSC-OPC-trans-
plantedmice, we next sought to confirm that this was associated
with the formation of ultrastructurally compact myelin around
host axons by hiPSC OLs. To this end, we used electron micros-
copy on samples of corpus callosum derived from 22- to 36-
week-old engrafted shiverers (n = 3). These mice comprised
animals that had been subjected to the five-site injection
protocol and survived significantly longer than their unengrafted
controls; these apparently rescued mice were killed after rela-
tively long survival time points to permit assessment of their
myelin integrity and quality. We found that their recipient callosa
were densely myelinated by mature compact myelin character-
ized by concentrically organized major dense lines (Figures
7A–7E) and interlaminar tight junctions (Figures 7F, 7G, and258 Cell Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier IncS4C); the engrafted callosa were quite unlike those of their un-
transplanted shiverer controls, which failed to exhibit major
dense lines or any other evidence of myelin compaction (Figures
S4B, S4D, and S4E).
Anatomic reconstitution of nodes of Ranvier was also noted
in these mice, as determined by immunolabeling of Caspr
and ßIV spectrin, which respectively identified paranodal and
nodal segments of newly myelinated axons (Figures 7H and
7I). In past studies, we correlated the anatomic and antigenic
reconstitution of nodal architecture with the restoration of
both rapid conduction and functional competence (Windrem
et al., 2008). The rapid and robust reacquisition of nodal archi-
tecture in these mice suggests that hiPSC-derived OLs
generate the cues necessary for the nodal organization of
axonal proteins, upon which the formation of functional nodes
of Ranvier depends..
Figure 6. hiPSC OPCs Myelinate Widely to
Greatly Extend the Survival of Hypomyeli-
nated Mice
(A) Dot map indicating the distribution of hiPSC-
derived donor cells (C27) at 7 months of age, fol-
lowing neonatal engraftment in a shiverer mouse
brain. Widespread dispersal and chimerization by
hiPSC OPCs is evident (hNA, red).
(B) hiPSC-OPC-derived myelination in a shiverer
forebrain at 7 months; section 1 mm lateral
to (A). MBP immunoreactivity (green) is all donor
derived.
(C and D) Myelination in sagittal sections taken at
different mediolateral levels from two additional
7-month-oldmice, each engraftedwith C27 hiPSC
OPCs at birth.
(E) Kaplan-Meier plot of the survival of C27
iPSC-OPC-implanted (n = 22) versus saline-in-
jected (n = 19) control mice. Remaining engrafted
mice sacrificed for electron microscopy at
9–10 months (R270 days).
Scale: 2 mm (A and B). See also Figure S3.
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efficiently generate OLs, which in turn can robustly myelinate
the hypomyelinated shiverer forebrain, and that the myelin
thereby generated is able to restore nodal architecture as well
as to ensheath axons as efficiently as purified isolates of fetal-
tissue-derived OPCs.
hiPSC OPCs Were Nontumorigenic In Vivo
The persistence of undifferentiated pluripotent stem cells may
cause either teratomas or neuroepithelial tumors in graft recipi-
ents (Roy et al., 2006). To assess whether any pluripotent or
incompletely differentiated hESCs or hiPSCs remained in nomi-
nally fully differentiated OL cultures, we used both immunolabel-
ing and qRT-PCR to assess the expression of pluripotent
markers by late-stage hiPSC-derived OPCs. By 100 DIV, no
detectable OCT4, NANOG, or SSEA4 protein could be found
in OPCs derived from any of the hESC and hiPSC lines used
in this study. Similarly, qRT-PCR revealed that transcripts of
OCT4 and human telomerase reverse transcriptase (hTERT)
were downregulated to essentially undetectable levels by 95 or
more DIV (Figures S2J and S2K). We also examined the in vivo
expression of OCT4, NANOG, and SSEA4 by engrafted OPCs
3 months after transplantation. As noted, only a small minority
of hNA+ donor cells were unstained by OLIG2, MBP, or GFAP.
Many donor-derived cells expressed nestin or SOX2, suggesting
their persistence as neural progenitors, but no persistent expres-
sion of OCT4, NANOG, or SSEA4 was detectable in any of these
cells, from any of the lines assessed.
Accordingly, we found no evidence of teratoma formation in
any of the 16 shi/shi 3 rag2/ mice examined for this purpose,
which included mice transplanted neonatally with 100,000 cells
and killed either 3 (n = 11) or 4.5 (n = 5) months later. We also
examined available mice in our survival series, all of whom hadCell Stem Cell 12, 252–264been transplanted at five sites with a total
of 300,000 cells and had died between
4 and 9 months of age (n = 10); none
had any evidence of teratomas, hetero-topias, or any type of tumor formation. In addition, we trans-
planted hiPSCs into normally myelinated rag2-null mice to
assess tumorigenicity in the wild-type myelin environment as
well. Of five mice examined 6 months after transplantation,
none showed any evidence of tumor formation, heterotopias,
or even foci of undifferentiated expansion. Of note, persistent
expression of SOX2, KLF4, and c-MYC mRNA was noted by
qPCR in the hiPSC-derived cells, reflecting some level of unsi-
lenced expression of the lentivirally inserted reprogramming
genes; nonetheless, the expression of the these transcripts
was not associated with tumorigenesis by cells transplanted at
the end of stage 6.
The lack of tumor formation in hiPSC-OPC-engrafted mice
was associated with a significant decrease in the mitotic fraction
of the implanted hiPSC OPCs as a function of time after graft.
hiPSC OPC proliferation in vivo was measured as Ki67 expres-
sion by all human donor cells, which was noted to decrease line-
arly from 3 months (13.6 ± 0.6%) to 6 months (4.3 ± 0.04%) of
age (R2 = 0.9; p = 0.001; n = 7).
To establish the role of our differentiation protocol in diminish-
ing the risk of tumorigenesis, we also transplanted rag2-null mice
with both C27 and K04 hiPSCs at the end of stages 1 and 3. This
was also done as a positive control for tumor detection, given our
lack of observed tumors in the hiPSC OPC (stage 6)-engrafted
mice, as much as 9 months after transplant. Yet in contrast to
the hiPSC-OPC-engrafted mice, which were entirely tumor-
free, every animal engrafted with earlier-stage hiPSCs mani-
fested histologically overt tumor formation by 3 months (n = 8
mice engrafted with stage 1 hiPSCs; n = 6 with stage 3 cells).
Thus, our differentiation protocol appeared to effectively deplete
the donor cell pool of persistent undifferentiated cells; the resul-
tant grafts of hiPSC OPCs proved uniformly nontumorigenic
when studied as long as 9 months after transplant., February 7, 2013 ª2013 Elsevier Inc. 259
Figure 7. hiPSC-Derived OLs Produce Compact Myelin and Induce Nodes of Ranvier
Representative electron microscopic images of sections through the corpus callosum (A and B) and ventral pons (C) of a 40-week-old shiverer mouse neonatally
engrafted with C27 hiPSC OPCs, showing donor-derived compact myelin with evident major dense lines, ensheathing mouse axons.
(D–G) Higher-power images of donor-derivedmyelin in the corpus callosum, also at 40weeks. (D and E) The alternatingmajor dense (arrowheads) and intraperiod
lines, characteristic of mature myelin, are evident. (F and G) Myelin sheaths in the corpus callosum ensheathing central axons are shown, their maturation
manifested by parallel arrays of tight junctions (F, arrowhead) and major dense lines (G, arrowhead).
This mature myelination permitted the organization of architecturally appropriate nodes of Ranvier by hiPSC oligodendroglia. In (H) and (I), nodal reconstitution in
transplanted shiverers is demonstrated by immunostaining of oligodendrocytic paranodal Caspr protein (red), seen flanking nodes of Ranvier identified here by
ßIV spectrin (green). An isolated node is shown in confocal cross-section in (I).
Scale: 200 nm (A–E); 100 nm (F and G); and 5 mm (H and I). See also Figure S4.
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In this study, we established the feasibility of using hiPSCs to
generate highly enriched populations of both astrocytes and
myelinogenic central OLs, with high efficiency and yield. The
success of our protocol in all four lines used in this study, which
include WA09/H9 hESCs and K04, C14, and C27 iPSCs,
suggests its broad applicability, and the highly efficient gliogen-
esis afforded by this strategy indicates its robust nature. Most
importantly, the robust myelination that we noted in vivo, which
compared favorably to that previously demonstrated by tissue-
derived fetal human glial progenitors, suggested the probable
functional integration and utility of these grafts. Accordingly,
we noted that myelination-deficient shiverers engrafted neona-
tally with hiPSC OPCs survived substantially longer than did
both their untransplanted and saline-injected controls; indeed,
over three-fourths of hiPSC-OPC-transplanted mice survived
over 6 months, long after all untreated control mice had died.
As a result, we can now reliably produce hiPSC OPCs from
single-patient skin samples in sufficient numbers to provide
myelinogenic autografts largely, though perhaps not completely
(Zhao et al., 2011), free of rejection risk.
Importantly, the myelination efficiency of the implanted iPSC-
derivedOPCs, defined as the proportion of central axonsmyelin-
ated as a function of time after graft, proved as high as that which
we had previously achieved using tissue-derived, CD140a-
sorted OPCs (Sim et al., 2011). Indeed, it was remarkable to
note that the proportion of axons ensheathed was as high in en-
riched but unsorted hiPSC-OPC grafts as in fetal-tissue-derived
OPC grafts that had been sorted for CD140a+ cells prior to trans-
plant. Indeed, the hiPSC-OPCs grafts myelinated more axons
more rapidly than did A2B5/PSA-NCAM-sorted fetal-tissue-
derived cells, probably reflecting the higher proportion of bipo-
tential glial progenitor cells in the hiPSC-OPC populations by
the time of their harvest and transplantation.
In light of the robust myelination afforded by hiPSC-OPC
grafts, we asked whether neonatal transplantation of hiPSC
OPCs might be sufficient to rescue the phenotype and survival
of recipient shiverer homozygotes, as we had previously ob-
served in a minority of shiverers transplanted with fetal-human-
brain-derived OPCs. We found that the hiPSC-OPC-trans-
planted mice indeed exhibited markedly improved survival;
death was both delayed and reduced overall in the transplanted
group over the 9 month period of observation. As we had previ-
ously documented with fetal-brain-tissue-derived OPC grafts,
the rescued mice manifested progressive resolution of their
neurological deficits (Windrem et al., 2008). Remarkably,
however, the proportion of animals whose survival benefitted
from hiPSC-OPC transplantation was substantially higher than
that which we previously reported using tissue-derived human
OPCs: whereas we had observed that only one-quarter of
shiverer mice transplanted with tissue-derived OPCs survived
beyond 6 months of age (Windrem et al., 2008), in our present
study over half of the hiPSC-OPC-engrafted mice did so (Fig-
ure 6E). Nonetheless, some later deaths beyond 7 months
of age were still noted; this may reflect an inhomogeneous
dispersal of hiPSC OPCs that we observed in some animals,
the nature of which we continue to investigate. Those late deaths
notwithstanding, at least one-fifth of themice appeared to repre-Cesent outright clinical rescues, though we sacrificed these survi-
vors atR 9 months for histological and ultrastructural analysis.
These provocative data suggest the superiority of hiPSC OPCs
as therapeutic vectors, perhaps by virtue of their more rapid
myelinogenesis, whichmay be a function of the prolonged differ-
entiation conditions that we employed in our OPC induction
protocol.
Interestingly, we observed no evidence of tumorigenesis from
implanted hiPSC-derived glial progenitors, at time points as long
as 9 months after transplant. This was surprising, given that
previous studies had provided ample evidence for the risk of
tumor formation from either residual undifferentiated cells (Prus-
zak et al., 2009) or from partially differentiated neuroepithelial
cells in hESC-derived transplants (Roy et al., 2006). It is possible
that the prolonged differentiation protocols that we employed to
produce OPCs are robust enough to effectively eliminate any
residual undifferentiated cells prior to transplantation. It is simi-
larly possible that epigenetic marks persisting in reprogrammed
hiPSCs effectively lowered the later risk of tumorigenesis by their
differentiated derivatives. In any case, even longer survival time
points will be needed, with more animals and an intensive search
for any residual undifferentiated and/or potentially tumorigenic
cells in vivo, before we can confidently state the safety of these
grafts. Should tumorigenesis at any point be a concern, then
hiPSC OPCs may be sorted to purity before transplantation, on
the basis of the high incidence of definitively pro-oligodendro-
cytic CD9+/CD140a+ cells in our cultures, and our ability to iso-
late these cells by fluorescence-activated cell sorting (FACS)
based upon these coexpressed epitopes (Sim et al., 2011).
These findings indicate that high-efficiency in vivo oligoden-
drocytic differentiation and myelination can be achieved from
hiPSCs, suggesting the potential utility of iPSC-derived auto-
grafts in treating acquired disorders of myelin. Yet it is also
important to note the efficient, context-dependent generation
of both fibrous and protoplasmic astrocytes from engrafted
hiPSC OPCs. Besides the importance of astroglia in effecting
the structural and physiological reconstitution of dysmyelinated
tracts, astrocytic engraftment may be of particular importance
in correcting dysmyelinating disorders of enzyme deficiency,
given that astrocytic lysosomal enzymes have been found to
readily transit from wild-type to deficient glia within brain tissue,
in a manner potentially sufficient to rescue enzyme-deficient
hosts (Lee et al., 2007). In addition, hiPSC-derived astrocytes
may prove to be critically important therapeutic vectors for
diseases of primarily astrocytic pathology (Krencik et al., 2011),
such as Alexander disease and the vanishing white-matter disor-
ders (Bugiani et al., 2011), in which myelin loss occurs but may
be secondary to astrocytic dysfunction. In each of these cases,
however, the therapeutic use of iPSC-derived astroglia will need
to be paired with methods for the ex vivo correction of the
genetic defects characteristic of these disorders.
Human iPSC OPCs might thus be attractive vectors for
restoring or replacing glial populations in a variety of disease
settings. Most critically, our data suggest the preferential use
of hiPSC-derived OPCs to restore lost myelin in disorders such
as multiple sclerosis and traumatic demyelination, in which no
genetic abnormalities might complicate the use of a patient’s
own somatic cells as the iPSC source. iPSC OPCs may similarly
prove of great therapeutic value in genetic disorders of myelin,ll Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Inc. 261
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underlying genetic defect must first be repaired in the donor
somatic cells before glial progenitor induction and implantation.
Our present study thus establishes the technical feasibility and
efficacy of generating myelinogenic OLs from hiPSCs and
suggests the clinical situations in which this approach might be
most appropriate. We may now reasonably contemplate the
clinical application of patient-specific, somatic cell-derived glial
progenitor cell transplants for the treatment of acquired disor-
ders of myelin, as well as of the broader spectrum of human glial
pathologies.
EXPERIMENTAL PROCEDURES
hESC and hiPSC Culture
We used four distinct lines of pluripotent cells in this study. These included
hESCs (WA09/H9; WiCell, Madison, WI, USA) and hiPSCs of both keratinocyte
(K04; K. Hochedlinger) and fibroblast origin (C14 and C27 hiPSCs; L. Studer).
The experiments described were approved by the University of Rochester
Embryonic Stem Cell Research Oversight committee.
OPC Production
OPCs were induced from hESCs and iPSCs using our modifications of pub-
lished protocols (Hu et al., 2009a; Hu et al., 2009b; Izrael et al., 2007), as sche-
matized in Figure 1 and described in detail in the Supplemental Experimental
Procedures.
Directed Astrocytic or Oligodendrocytic Maturation
hiPSC- or hESC-derived gliogenic spheres at 120–170 DIV were cultured in
suspension in GIM supplemented with platelet-derived growth factor-AA
(PDGF-AA; 10 ng/ml), insulin growth factor-1 (IGF-1; 10 ng/ml) and Neurotro-
phin-3 (NT3; 10 ng/ml). To differentiate these OPCs into mature OLs or
astrocytes, the spheres were dissected into small cell clusters (around 50–
100 mm in diameter) mechanically with a Sharpoint blade (Surgimed-MLB).
The dissected OPC clusters were plated onto polyornithine/laminin-coated
12-well plates and cultured in GIM for 1–2 weeks. For induction of astrocytes,
the OPC clusters were cultured either in GIM supplemented with PDGF-AA
(10 ng/ml), IGF-1 (10 ng/ml), and NT3 (10 ng/ml) or in GIM supplemented
with 10% fetal bovine serum (FBS; HyClone) for 1–2 weeks. For directing the
maturation of OLs, the cultures were switched to half GIM supplemented
with PDGF-AA (5 ng/ml), IGF-1 (5 ng/ml), and NT3 (5 ng/ml) plus half neuro-
basal (NB) media (Invitrogen) supplemented with B27 (1X) and brain-derived
neurotrophic factor (BDNF; 10 ng/ml) and grown for 2–4 weeks. The mature
astrocytes were recognized with immunostaining of anti-GFAP or anti-CD44.
Oligodendroglia were identified using O4 and MBP antibodies.
In Vitro Immunocytochemistry
All in vitro fixation and immunolabeling protocols are detailed in the Supple-
mental Experimental Procedures.
Isolation of Human Fetal Neuronal Progenitor Cells for Coculture
Human fetal forebrain tissue was obtained from second-trimester aborted
fetuses of 20 weeks g.a. Tissues were obtained as deidentified tissue, as
approved by the Research Subjects ReviewBoard of the University of Roches-
ter Medical Center. The tissue samples were washed 2–3 times with sterile
Hank’s balanced salt solution with Ca2+/Mg2+ (HBSS+/+). Cortical plate tissue
was separated from the ventricular zone/subventricular zone, then dissociated
with papain (Worthington Biochemical) as described (Keyoung et al., 2001;
Wang et al., 2010). The cells were resuspended at 2–4 3 106 cells/ml in Dul-
becco’s modified Eagle’s medium (DMEM)/F12 supplemented with N-2
supplement (Life Technologies) and basic fibroblast growth factor (bFGF;
20 ng/ml) and plated in suspension culture dishes. A day later, the cells were
recovered and neurons isolated by magnetic-activated cell sorting (Windrem
et al., 2008). In brief, the recovered neural progenitor cells were incubated
with PSA-NCAM (Chemicon) at 1:100 for 30 min, then washed and labeled
with rat anti-mouse immunoglobulin M microbeads (Miltenyi Biotech). The262 Cell Stem Cell 12, 252–264, February 7, 2013 ª2013 Elsevier Incbound PSA-NCAM+ neurons were eluted, spun, washed with DMEM/F12,
and then cultured in DMEM/F12 with N2, 0.5% PD-FBS, and bFGF
(20 ng/ml) for 4–6 days. For coculture with hiPSC OPCs, the fetal cortical
neurons were dissociated into single cells and then plated onto either poly-
L-ornithine/laminin-coated 24-well plates or poly-L-ornithine/fibronectin-
coated coverslips (50,000–100,000 cells per well or coverslip). The replated
neurons were then switched to NB media with B27 (1X) and BDNF
(10 ng/ml; Invitrogen) for an additional 6–10 days prior to coculture.
Coculture of hiPSC-Derived OPCs with Human Fetal Cortical
Neurons In Vitro
Gliogenic OPC spheres derived from either K04 or C27 hiPSCs were induced
up to 130 DIV prior to coculture. These were dissected into small pieces
of <1mm3 and cultured for 2–3 weeks to allow the OPCs to expand as amono-
layer surrounding the core clusters. The OPC clusters and their monolayer
surrounds were then recollected with cold HBSS/ from the culture dishes
and manually dissected into smaller fragments of 100–200 mm in diameter.
Small aliquots were fully dissociated into single cells with Accutase (Chemi-
con) for 5 min at room temperature, then assessed by hemocytometry. For
coculture, the hiPSC OPCs were then seeded at 200,000 cells/ml, either
with or without human cortical neurons, and cultured in a 1:1 mixture of NB/
B27/BDNF and GIM/NT3/IGF-1/PDGF-AA media. The cultures of cortical
neurons alone, hiPSC OPCs alone, or both populations together were allowed
to grow 2–4 additional weeks before fixation and immunolabeling for O4, MBP,
GFAP, and ßIII-tubulin.
Flow Cytometry
Flow-cytometric methods, by which hESC- and hiPSC-derived OPCs were
analyzed for A2B5, CD140a, CD9, and O4 immunoreactivities, as well as the
cell preparation methods antecedent to cytometry and sorting, are described
in detail in the Supplemental Experimental Procedures.
RNA Extraction and RT-PCR
Total RNA was extracted from undifferentiated hESCs and hiPSCs, or hESC-
and hiPSC-derived OPCs, using RNeasy mini kit (QIAGEN). The first of strand
of complementary DNA was transcribed using the TaqMan Reverse Tran-
scription kit (Roche #N808-0234). The primer sequences are given in the
Supplemental Experimental Procedures. The relative abundance of transcript
expression of mRNAs was measured with the ABI PRISM 7000 system. The
resultant expression data were normalized to the expression level of glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Statistical analysis
was performed on transformed data. The means and SEM were calculated
following a paired t test.
Neonatal Xenograft into Shiverer Mice
Homozygous shiverer mice (The Jackson Laboratory, Bar Harbor, ME, USA)
were crossed with homozygous rag2-null immunodeficient mice (Shinkai
et al., 1992) on the C3H background (Taconic, Germantown, NY, USA) for
generation of shi/shi 3 rag2/ myelin-deficient, immunodeficient mice. The
hiPSC-derived OPCs were prepared for transplantation as described for
in vitro coculture. Neonatal pups were either transplanted bilaterally in the
corpus callosum with a total of 100,000 cells, as described in Windrem
et al., 2004, or with 300,000 cells, using the procedure described in Windrem
et al., 2008. At 3 months of age, transplanted mice were anesthetized with
pentobarbital, then perfusion fixed with cold HBSS+/+ followed by 4% parafor-
maldehyde. All procedures were approved by the University Committee on
Animal Resources. Brains were extracted and postfixed for 2 hr in cold para-
formaldehyde. Brains processed for electronmicroscopy were perfused in 4%
paraformaldehyde and 0.25% glutaraldehyde.
Immunohistochemistry of Tissue Sections
Human cells were identified with mouse anti-hNA, clone 235-1 (MAB1281
at 1:800; Millipore, Billerica, MA, USA). Phenotypes were identified with
human-specific NG2 (MAB2029 at 1:200; Millipore), rat anti-MBP (Ab7349 at
1:25), rabbit anti-OLIG2 (Ab33427 at 1:1000; Abcam, Cambridge, MA, USA),
human-specific mouse anti-GFAP (SMI-21 at 1:500), mouse anti-NF (SMI-
311 and SMI-312 at 1:1,000; Covance, Princeton, NJ, USA), and rabbit
anti-Ki67 (RM-9106 at 1:200; Thermo-Fisher, Freemont, CA, USA). Alexa Fluor.
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Myelination by Human iPSC OPCssecondary antibodies, including goat anti-mouse, -rat, and -rabbit antibodies
conjugated to 488, 568, 594, and 647 nm fluorophores, were used at 1:400
(Invitrogen, Carlsbad, CA, USA). PAX6, NKX2.2, OCT4, NANOG, and SOX2
antibodies were employed using the same conditions as in vitro.
Morphometrics
Myelinated Axon Counts
Regions of dense engraftment with human cells were selected for NF and
MBP staining; a 1 mm stack of ten superimposed optical slices taken at
0.1 mm intervals (Olympus FluoView 300) was made for each of three fields
of view in the corpus callosum. Three parallel, equidistant lines were laid
over the images perpendicular to the axons. Axons were scored at intersec-
tions with the lines as either myelinated (closely apposed to MBP on both
sides) or unmyelinated.
Mapping of Human Cell Engraftment
The positions of all anti-human nuclei+ cells were mapped on 20 mm coronal
sections at 160 mm intervals from 3.2 to 1.2 bregma anterior-posterior.
Cell Counting
Three unilateral, equally spaced samples of corpus callosum, from0.4 to 1.2
bregma, were counted for cells expressing hNA together with either MBP,
hGFAP, OLIG2, or Ki67. White matter was also assessed for the presence of
any hNA+ cells coexpressing HuC/HuD, OCT4, or NANOG. All data are
provided as means ± SEM.
Electron Microscopy
Samples of human iPSC-derived glial chimeric white matter were taken from
mice killed at 22–40 weeks of age, perfused with half-strength Karnovsky’s
fixative, then processed for ultrastructural analysis of myelin morphology
and quality using previously described techniques (Windrem et al., 2008).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.stem.2012.12.002.
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